FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
BioSyent Inc. Stock AnalysisComprehensive stock analysis for BioSyent Inc. (RX.V) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisRX.V
RX.V
BioSyent Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
RX.V
Home🔹Stocks🔹BioSyent Inc.

BioSyent Inc.

RX.V•TSXV

BioSyent Inc.

RX.V•TSXV
Market cap
$87.35M
Sentiment

Your view on RX.V

Mkt Cap
$87.35M
Sentiment
Your view
RX.V
BioSyent Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
RX.V
Company Overview

Overview

What the company does, where it operates, and who runs it.

About BioSyent Inc.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
René C. Goehrum
Headquarters
2476 Argentia Road, Mississauga, ON, CA
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
René C. Goehrum
Headquarters
2476 Argentia Road, Mississauga, ON, CA
Description

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News